-
ASH News Flash | Professor Huanling Zhu Highlights Breakthrough Leukemia Studies
The 2025 Annual Meeting of the American Society of Hematology (ASH) was held from December 6–9 in Orlando, USA, drawing global attention as one of the most influential international conferences…
-
ASH China Voices | Prof. Yongrong Lai & Prof. Lingling Shi: Validation of the “Guangxi Regimen” for Thalassemia Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for transfusion-dependent thalassemia (TDT). However, transplant outcomes are influenced by donor type, transplant-related complications, and patient-specific factors, leaving room…
-
Focusing on Non–Clear Cell Renal Cell Carcinoma: From Precision Diagnosis to Personalized Treatment—Exploration and Practice
Editor’s Note: Non–clear cell renal cell carcinoma (nccRCC) remains one of the most challenging areas in kidney cancer owing to its marked heterogeneity, low incidence, and complexity in diagnosis and…
-
2025 Tianjin International Breast Cancer Conference |Professor Zhang Juliang: Skip the “Grand Narrative”—Even Small Questions Can Lead to Big Papers! Expert Advice on How Early- and Mid-Career Doctors Can Break Through With IITs
From “following evidence” to “creating evidence”, clinical research in breast cancer in China is entering a deep phase of high-quality development. Within the grand framework of precision medicine, industry-sponsored trials (ISTs) may serve as the gateway for innovative drugs to enter clinical practice, but investigator-initiated trials (IITs) are the master key to solving the “last…
-
SABCS Expert Commentary | Professor Jin Feng: Reanalysis of the Landmark NSABP B-20 Trial—Can MMAI Become a Low-Cost Option for Risk Stratification?
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a reanalysis of the landmark NSABP B-20 trial (Abstract No. RF3-03) was presented, exploring the prognostic value and chemotherapy benefit–predictive potential of a multimodal artificial intelligence (MMAI) model based on digital pathology and clinical data in hormone receptor–positive (HR+), node-negative early breast cancer.
-
SABCS Expert Commentary |Professor Jin Feng: Deep Learning Accurately Predicts Late Distant Metastasis in HR-Positive Early Breast Cancer and Guides Decisions on Extended Endocrine Therapy
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study based on data from the NSABP B-42 and TAILORx trials (Abstract No. RF3-07) reported the development and validation of a multimodal, multitask deep learning model (Clarity BCR). By integrating routine digital pathology images with key clinical variables, this model accurately predicts the risk…
-
SABCS Expert Commentary |Professor Jin Feng: New Evidence for Precision Immunotherapy in Early Triple-Negative Breast Cancer—Gene Expression Subtyping Predicts Response to Neoadjuvant Immunochemotherapy
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study titled “Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. The study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early triple-negative breast…
-
SABCS Expert Commentary | Professor Mao Xiaoyun: The ALTTO Study Confirms Superior DFS With Aromatase Inhibitors Over SERMs, Providing New Evidence for Endocrine Therapy in HR+/HER2+ Breast Cancer
In patients with HR-positive/HER2-positive early breast cancer, adjuvant anti-HER2 therapy constitutes the cornerstone of systemic treatment. However, robust high-level evidence has long been lacking to guide the choice between aromatase inhibitors (AIs) and tamoxifen (SERMs) for adjuvant endocrine therapy in this population.
Connecting Medical Expertise through Media